<p>Hengrui Pharma (01276.HK) announced that the company's subsidiary Shanghai Hengrui's injectable SHR-A1904 has been included in the list of breakthrough therapy varieties by the National Medical Products Administration's Drug Evaluation Center. The proposed indication is for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that is CLDN18.2 positive and has previously received at least first-line systemic treatment</p>

600276

01276

<p>Hengrui Pharma announced that the company and its subsidiary Shanghai Hengrui's injectable SHR-A1904 have been included in the list of breakthrough therapy products by the National Medical Products Administration's Drug Evaluation Center. The proposed indication is for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that is CLDN18.2 positive and has received at least first-line systemic treatment</p>

Hengrui Pharma's injectable SHR-A1904 has been included in the breakthrough therapy list